



TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: +91 79 26599000 Fax: + 91 79 26582100
CIN: L24230GJ1972PLC002126; Website: www.torrentpharma.com; Email: investorservices@torrentpharma.com

(Rs. in Crores except per share data)

Statement of Standalone Audited Results for the Quarter Ended 30-Jun-2018


Particulars	Quarter ended			Year ended
	30-Jun-2018	31-Mar-2018	30-Jun-2017	31-Mar-2018
Revenue				
Net sales	1415	1292	834	4138
Other operating income	37	40	13	106
Revenue from operations (net)	1452	1332	847	4244
Other income	34	51	109	332
Total revenue	1486	1383	956	4576
Expenses				
Cost of materials consumed	310	322	239	995
Purchases of stock-in-trade	92	113	70	353
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4)	(67)	(88)	(232)
Employee benefits expense	252	231	187	826
Finance costs	117	117	55	294
Depreciation and amortisation expense	141	143	74	384
Other expenses	390	441	318	1394
Total expenses	1298	1300	855	4014
Profit before tax	188	83	101	562
Tax expense				
Current Tax	41	18	22	121
Deferred Tax	25	(155)	(5)	(41)
Total tax expense	66	(137)	17	80
Net profit for the period	122	220	84	482
Other comprehensive income				
Items that will not be reclassified to profit or loss	(1)	5	(3)	(3)
Income tax relating to items that will not be reclassified to profit or loss	-	(2)	1	1
Items that will be reclassified to profit or loss	(71)	(51)	(67)	(172)
Income tax relating to items that will be reclassified to profit or loss	25	17	23	59
Total other comprehensive income	(47)	(31)	(46)	(115)
Total comprehensive income	75	189	38	367
Paid-up equity share capital (Face value of Rs. 5 each)	84.62	84.62	84.62	84.62
Other Equity excluding Revaluation Reserves				4472
Earnings per share (of Rs. 5/- each) (not annualised for the quarter):				
Basic	7.21	12.95	4.97	28.48
Diluted	7.21	12.95	4.97	28.48



Notes:

- 1 The above results were reviewed by the Audit and Risk Management Committee and approved by the Board of Directors in their respective meetings held on 02-August-2018. The auditor have carried out an audit of the above said results. There is no qualification in the Auditors report on this statement of financial results.
- 2 The Company operates in a single segment i.e Generic Formulation Business.
- 3 The Company has acquired branded business of Unichem Laboratories Limited for India and Nepal on a going concern basis by way of slump sale on 14-Dec-2017. The quarter ended 30-Jun-2018 and the quarter and year ended 31-Mar-2018 includes revenue and expenses (including amortisation and interest) of the acquired business.
- 4 (a) The listed Non Convertible Debentures of the company aggregating Rs. 1315 crores as on 30-Jun-2018 (previous year ended Rs. 1399 crores) are secured by way of first pari passu charge created through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
(b) The listed Non Convertible Debentures of the company aggregating Rs. 1000 crores as on 30-Jun-2018 (previous year ended Rs. 1000 crores) to be secured by way of first pari passu charge on certain specified immovable & movable assets and identified trademarks of the Company.
- 5 Effective 1 April 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Company.
- 6 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

For TORRENT PHARMACEUTICALS LIMITED



SAMIR MEHTA
Executive Chairman

Place : Ahmedabad, Gujarat

Date : 02-August-2018

